Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.
Benardeau, A., Benz, J., Binggeli, A., Blum, D., Boehringer, M., Grether, U., Hilpert, H., Kuhn, B., Marki, H.P., Meyer, M., Puntener, K., Raab, S., Ruf, A., Schlatter, D., Mohr, P.(2009) Bioorg Med Chem Lett 19: 2468-2473
- PubMed: 19349176 
- DOI: https://doi.org/10.1016/j.bmcl.2009.03.036
- Primary Citation of Related Structures:  
3G8I, 3G9E - PubMed Abstract: 
Design, synthesis, and SAR of novel alpha-alkoxy-beta-arylpropionic acids as potent and balanced PPARalphagamma coagonists are described. One representative thereof, Aleglitazar ((S)-2Aa), was chosen for clinical development. Its X-ray structure in complex with both receptors as well as its high efficacy in animal models of T2D and dyslipidemia are also presented.
Organizational Affiliation: 
F. Hoffmann-La Roche Ltd, Pharma Research, CH-4070 Basel, Switzerland.